Abstracts tagged "gastrointestinal complications"

Abstract Number: 2368 • 2019 ACR/ARP Annual Meeting
Risk of Diverticulitis and Gastro-Intestinal Perforation in Rheumatoid Arthritis Treated with Tocilizumab Compared to Rituximab and Abatacept: A Prospective Propensity-matched Cohort Study
Claire Rempenault¹, Cédric Lukas ¹, Bernard Combe ², Isabelle Pane ³, Xavier Mariette ⁴, Jacques-Eric Gottenberg ⁵ and Jacques Morel ¹, ¹Department of Rheumatology, Montpellier University Hospital, Montpellier, France, Montpellier, Languedoc-Roussillon, France, ²CHU Montpellier, Montpellier University, Montpellier, France, ³Centre de Recherche en Epidémiologie et Statistiques, INSERM U1153, Centre d'Épidémiologie Clinique, Hôpital Hôtel-Dieu, Assistance Publique-Hôpitaux de Paris (AP-HP), Descartes University, Paris, France., Paris, Ile-de-France, France, ⁴Center for Immunology of Viral Infections and Autoimmune Diseases, Assistance Publique – Hôpitaux de Paris, Hôpitaux Universitaires Paris-Sud, Le Kremlin-Bicêtre, Université Paris Sud, INSERM, Paris, France, ⁵Department of Rheumatology, Strasbourg University Hospital, Strasbourg, France
Background/Purpose: Several studies have reported an increased risk of gastro-intestinal perforation (GIP) in rheumatoid arthritis (RA) patients treated with tocilizumab (TCZ) compared to conventional synthetic…
Abstract Number: 1105 • 2018 ACR/ARHP Annual Meeting
Abatacept Is Effective in Experimental Digestive and Lung Tissue Fibrosis
Gonçalo Boleto¹, Christophe Guignabert², Sonia Pezet³, Anne Cauvet³, Jérémy Sadoine⁴, Ly Tu², Carole Nicco³, Camille Gobeaux⁵, Frederic Batteux³, Yannick Allanore³ and Jérôme Avouac¹, ¹Université Paris Descartes, Sorbonne Paris Cité, Service de Rhumatologie A, Hôpital Cochin, Paris, France, Paris, France, ²INSERM UMR_S 999, Le Plessis-Robinson, France, Le Plessis-Robinson, France, ³Université Paris Descartes, Sorbonne Paris Cité, INSERM U1016, Institut Cochin, CNRS UMR8104, Paris, France, Paris, France, ⁴EA 2496 Pathologie, Imagerie et Biothérapies Orofaciales, UFR Odontologie, Université Paris Descartes and PIDV, PRES Sorbonne Paris Cité, Montrouge, France, Montrouge, France, ⁵Clinical Chemistry Laboratory, Cochin and Hôtel-Dieu Hospitals, Paris, France, Paris, France
Background/Purpose: A previous report showed that abatacept (IgG-CTLA-4) prevented and induced regression of inflammation-driven dermal fibrosis in two different mouse models of systemic sclerosis (SSc)…
Abstract Number: 1725 • 2018 ACR/ARHP Annual Meeting
Fecal Microbiota Transplantation in Patients with Systemic Sclerosis- a Pilot Study
Håvard Fretheim¹, Oyvind Midtvedt¹, Anders Heiervang Tennøe¹, Henriette Didriksen¹, Torhild Garen¹, Espen Bækkevold¹, Johannes R. Hov¹, Knut EA Lundin², Marius Trøseid¹, Øyvind Molberg¹ and Anna-Maria Hoffmann-Vold¹, ¹Oslo University Hospital, Oslo, Norway, ²Dept of gastroenterology, Oslo University Hospital, Oslo, Norway
Background/Purpose: Up to 90% of patients with systemic sclerosis (SSc) have symptoms from the gastrointestinal (GI) tract. Earlier studies have shown a distinct alteration of…
Abstract Number: 1739 • 2018 ACR/ARHP Annual Meeting
What Do Patient Reported Outcomes for Routine Monitoring of Gastrointestinal Tract Symptoms in a Systemic Sclerosis Center Tell Us about Clinical Features of Potential Small Intestinal Bacterial Overgrowth?
Jessica Zhu¹, Craig Gale², Joshua Biber³, Mandana Nikpour⁴, Murray Baron⁵ and Tracy M. Frech⁶, ¹School of Medicine, University of Utah, Salt Lake City, UT, ²Bioinformatics, University of Utah, Salt Lake City, UT, ³University of Utah, Salt Lake City, UT, ⁴The University of Melbourne, Melbourne, Australia, Melbourne, Australia, ⁵Department of Medicine, McGill University, Montreal, QC, Canada, ⁶Division of Rheumatology, University of Utah, Salt Lake City, UT
Background/Purpose: The implementation of patient reported outcome measures (PROMs) is increasingly recognized as a critical aspect of clinical practice. The use of gastrointestinal (GI) PROMs…
Abstract Number: 1767 • 2018 ACR/ARHP Annual Meeting
Occurrence and Etiology of Gastrointestinal Perforation in Patients with Vasculitis
Vanessa L. Kronzer¹, Daniel Larson², Cynthia S. Crowson^3,4, Kenneth J. Warrington⁵, Steven R. Ytterberg⁵, Ashima Makol⁴ and Matthew J. Koster⁴, ¹Internal Medicine, Mayo Clinic, Rochester, MN, ²Pathology, Mayo Clinic, Rochester, MN, ³Health Sciences Research, Mayo Clinic College of Medicine and Science, Rochester, MN, ⁴Rheumatology, Mayo Clinic, Rochester, MN, ⁵Rheumatology, Division of Rheumatology, Mayo Clinic College of Medicine, Rochester, MN
Background/Purpose: This study aimed to characterize the presenting features and outcomes of patients with small- or medium-vessel vasculitis and gastrointestinal perforation. Methods: Using a retrospective…
Abstract Number: 2604 • 2018 ACR/ARHP Annual Meeting
Incidence of Serious Gastrointestinal Events and Inflammatory Bowel Disease Among Tildrakizumab-Treated Patients with Moderate to Severe Plaque Psoriasis: Data from 3 Large Randomized Clinical Trials
Melinda Gooderham¹, Boni E. Elewski², David M. Pariser³, Howard Sofen⁴, Alan M Mendelsohn⁵, Nicole Cichanowitz⁶ and Qing Li⁶, ¹Probity Medical Research, and Skin Center for Dermatololgy, Waterloo, and Peterborough, ON, Canada, ²University of Alabama at Birmingham, Birmingham, AL, ³Eastern Virginia Medical School and Virginia Clinical Research, Inc., Norfolk, VA, ⁴Ronald Reagan UCLA Medical Center, Department of Medicine (Dermatology) UCLA, Los Angeles, CA, ⁵Sun Pharmaceutical Industries, Inc., Princeton, NJ, ⁶Merck & Co., Inc., Kenilworth, NJ
Background/Purpose: Tildrakizumab (TIL), a high-affinity, humanized, immunoglobulin G1κ, anti–interleukin-23p19 monoclonal antibody, has demonstrated efficacy in the treatment of chronic plaque psoriasis.1,2 Here, we evaluate the…
Abstract Number: 2936 • 2018 ACR/ARHP Annual Meeting
Esophageal Erosion Predicts Progression of Lung Disease in Patients with Systemic Sclerosis
Silvia Laura Bosello¹, Enrico De Lorenzis¹, Gerlando Natalello², Giovanni Battista Canestrari¹, Laura Gigante¹, Lucrezia Verardi¹, Ludovica Berardini³ and Elisa Gremese¹, ¹Division of Rheumatology, Fondazione Policlinico Universitario A.Gemelli IRCCS, Catholic University of the Sacred Heart, Rome, Italy, ²Division of Rhematology, Fondazione Policlinico Universitario A.Gemelli IRCCS, Catholic University of the Sacred Heart, Rome, Italy, ³Division of Respiratory Medicine, Fondazione Policlinico Universitario A.Gemelli IRCCS, Catholic University of the Sacred Heart, Rome, Italy
Background/Purpose: Interstitial lung disease (ILD) is the leading cause of death in Systemic Sclerosis (SSc) but its pathogenesis is not fully understood. Esophageal disease is…
Abstract Number: 2939 • 2018 ACR/ARHP Annual Meeting
Clinical Features Associated with Severe Lower Bowel Involvement in Systemic Sclerosis
Eric Dein¹, Laura K. Hummers², Christopher A. Mecoli^3,4 and Zsuzsanna McMahan⁵, ¹Department of Internal Medicine, Johns Hopkins Bayview, Baltimore, MD, ²Medical and Rheumatology, Johns Hopkins University, Baltimore, MD, ³Internal Medicine/Rheumatology, Johns Hopkins University, Baltimore, MD, ⁴Rheumatology, Johns Hopkins University, Baltimore, MD, ⁵Department of Internal Medicine, Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: Although up to 90% of scleroderma (SSc) patients are affected by gastrointestinal (GI) dysmotility, clinical features of patients with severe lower gastrointestinal involvement are…
Abstract Number: 1248 • 2017 ACR/ARHP Annual Meeting
Evaluation of Validated Patient Reported Outcome Measures to Assess Sensitivity to Change in Patients with Systemic Sclerosis and Gastroesophageal Reflux Disease —a Scleroderma Clinical Trials Consortium Collaborative Project
Zsuzsanna McMahan¹, Tracy M. Frech², David Lim³, Veronica J. Berrocal⁴, Cosimo Bruni⁵, Marco Matucci-Cerinic⁶, Vanessa Smith⁷, Karin Melsons⁸, Susanna Proudman⁹, Jinyu Zhang¹⁰, Fabian A Mendoza¹¹, Melanie Woods³ and Dinesh Khanna³, ¹Department of Internal Medicine, Johns Hopkins University, Baltimore, MD, ²Division of Rheumatology, University of Utah, Salt Lake City, UT, ³University of Michigan, Ann Arbor, MI, ⁴Div of Rheumatology, University of Michigan, Ann Arbor, MI, ⁵Department of Experimental and Clinical Medicine, Division of Rheumatology, University of Florence, Firenze, Italy, ⁶Dept of Medicine/Div of Rheum, University of Florence, Firenze, Italy, ⁷Faculty of Internal Medicine, Ghent University, Ghent, Belgium, ⁸Ghent University, Gent, Belgium, ⁹Discipline of Medicine, University of Adelaide, Adelaide, Australia, ¹⁰Thomas Jefferson University, Philadelphia, PA, ¹¹Jefferson Institute of Molecular Medicine and Scleroderma Center, Rheumatology Division, Department of Medicine, Thomas Jefferson University, Philadelphia, PA
Background/Purpose: The UCLA SCTC GIT 2.0 and NIH PROMIS GI Symptoms Scales are validated in scleroderma to assess patient-reported gastrointestinal (GI) involvement. We sought to…
Abstract Number: 2668 • 2017 ACR/ARHP Annual Meeting
Responsiveness of University of California Los Angeles Scleroderma Clinical Trial Consortium (GIT2.0) and Intestinal Visual Analogue Scale to Change in Systemic Sclerosis Patients
Yossra A Suliman¹, Suzanne Kafaja², Mohamed Alemam³, yasser Shaweesh⁴, Kasra Tavakoli⁵ and Daniel E. Furst⁶, ¹Rheumatology and Rehabilitation dept., Rheumatology and Rehabilitation dept. Assiut university hospital, Assiut Egypt, Assiut, Egypt, ²Department of Internal Medicine, University of California Los Angeles, David Geffen School of Medicine, Division of Rheumatology, Los Angeles, CA, ³Clinical Pathology and Laboratory Medicine Department, Assistant Lecturer, Qena, Egypt, ⁴John H. Stroger Jr. Hospital of cook county, chicago, IL, ⁵Department of medicine, university of California Los Angeles, Los Angeles, CA, ⁶David Geffen School of Medicine at UCLA, Los Angeles, CA
Background/Purpose: Gastrointestinal tract (GIT) involvement in systemic sclerosis (SSc) is the most common internal organ involvement. Among the few validated patient-reported outcome measures for GI…
Abstract Number: 728 • 2017 ACR/ARHP Annual Meeting
Symptoms of Autonomic Dysfunction in Systemic Sclerosis Assessed By the Compass-31 Questionnaire
Brittany Adler¹, James Russell², Laura K. Hummers³ and Zsuzsanna McMahan⁴, ¹Rheumatology, Johns Hopkins University, Baltimore, MD, ²Neurology, Anatomy and Neurobiology, University of Maryland School of Medicine, Baltimore, MD, ³Medical and Rheumatology, Johns Hopkins University, Baltimore, MD, ⁴Department of Internal Medicine, Johns Hopkins University, Baltimore, MD
Background/Purpose: Autonomic dysfunction is a known complication of systemic sclerosis (SSc) and can affect vascular tone, gastrointestinal (GI) motility, and heart rate and blood pressure…
Abstract Number: 827 • 2016 ACR/ARHP Annual Meeting
Severe Gastrointestinal Disease in Early Systemic Sclerosis Is Associated with an Increased Risk of Mortality
Nicolas Richard¹, Marie Hudson², Mianbo Wang³, Murray Baron⁴, Genevieve Gyger¹ and Canadian Scleroderma Research Group, ¹McGill University, Jewish General Hospital, Montreal, QC, Canada, ²Medicine/Rheumatology, Jewish General Hospital, Lady Davis Research Institute, Montreal, QC, Canada, ³Lady Davis Institute for Medical Research, Montreal, QC, Canada, ⁴Rheumatology, McGill University, Jewish General Hospital, Montreal, QC, Canada
Background/Purpose: Studies of severe gastrointestinal (GI) disease in systemic sclerosis (SSc) are limited by small, selected samples composed largely of subjects with prevalent disease. We…
Abstract Number: 838 • 2016 ACR/ARHP Annual Meeting
Esophageal Dysmotility and Interstitial Lung Disease in Patients with Scleroderma: A Retrospective Study
Shweta Kishore¹, Santhanam Lakshminarayanan¹, Chia-Ling Kuo² and Ranadeep Mandhadi¹, ¹Division of Rheumatology, University of Connecticut, Farmington, CT, ²Department of Community Medicine and Health Care, University of Connecticut, Farmington, CT
Background/Purpose: Systemic sclerosis (SSc) is a connective tissue disease with pulmonary involvement seen in 75% of patients and esophageal involvement in 90% of the patients.…
Abstract Number: 839 • 2016 ACR/ARHP Annual Meeting
Immunosuppression Does Not Prevent Severe Gastrointestinal Disease in Systemic Sclerosis
Nicolas Richard¹, Marie Hudson², Mianbo Wang³, Murray Baron⁴, Genevieve Gyger¹ and Canadian Scleroderma Research Group, ¹McGill University, Jewish General Hospital, Montreal, QC, Canada, ²Medicine/Rheumatology, Jewish General Hospital, Lady Davis Research Institute, Montreal, QC, Canada, ³Lady Davis Institute for Medical Research, Montreal, QC, Canada, ⁴Rheumatology, McGill University, Jewish General Hospital, Montreal, QC, Canada
Background/Purpose: Severe gastrointestinal (GI) disease is associated with considerable morbidity and high mortality in systemic sclerosis (SSc). There are no known preventative treatments. We wished…
Abstract Number: 974 • 2016 ACR/ARHP Annual Meeting
Diffuse Scleroderma, Male Sex, and Myopathy Are Associated with Severe Gastrointestinal Dysmotility in Scleroderma
Zsuzsanna McMahan¹, Livia Casciola-Rosen² and Fredrick M. Wigley³, ¹Department of Internal Medicine, Johns Hopkins University, Baltimore, MD, ²Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ³Rheum Div/Mason F Lord, Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: Despite the fact that up to 90% of scleroderma (SSc) patients are affected by gastrointestinal (GI) dysmotility, features associated with severe GI disease are…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].